New gene test may spot hidden breast cancer in Hard-to-Diagnose lesions
NCT ID NCT07428733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether checking for certain gene changes (methylation of BRCA1, RASSF1A, and PTEN) in breast tissue samples can help doctors tell the difference between harmless and cancerous breast lesions. Researchers tested tissue from 401 women with breast lesions that were hard to diagnose using standard methods. The goal was to see if these gene tests could improve diagnostic accuracy and help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a more accurate diagnostic test for breast lesions, reducing unnecessary surgeries or missed cancers.
- What could go wrong
- This is a completed diagnostic study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not change current clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST LESIONS OF UNCERTAIN MALIGNANT POTENTIAL are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.